XCUR dividend history
Exicure Inc. (XCUR) dividend declarations and ex-dividend dates - real-time wire coverage of every payout disclosure.
Recent dividend items
- Exicure, Inc. Reports Full Year 2025 Financial ResultsREDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye
- Exicure, Inc. Reports Third Quarter 2025 Financial ResultsREDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended September 30, 2025. Third Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $4.4 million as of September 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended September 30, 2025, as compared to $0 for the quarter ended September 30, 2024. The increase in R&D expense of $0.9 million for the three months ended September 30, 2025 was due to incurring research and developmen
- Exicure, Inc. Reports Second Quarter 2025 Financial ResultsExicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended June 30, 2025. Second Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $7.9 million as of June 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended June 30, 2025, as compared to $0 for the quarter ended June 30, 2024. The increase in R&D expense of $0.9 million for the three months ended June 30, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. ("GPCR U
- Exicure, Inc. Reports First Quarter 2025 Financial ResultsExicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.8 million for the quarter ended March 31, 2025, as compared to $0 for the quarter ended March 31, 2024. The increase in R&D expense of $0.8 million for the three months ended March 31, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. ("G
- Exicure, Inc. Reports Full Year 2024 Financial ResultsExicure, Inc. (NASDAQ:XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. 2024 Financial Results Cash Posit
- Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial ResultsExicure, Inc. (NASDAQ:XCUR, the ", Company", )) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Equity Financing In an agreement dated November 6, 2024 and executed on November 12, 2024, the Company agreed to sell and issue to HiTron Systems Inc. ("HiTron") 433,333 shares of common stock, par value $0.0001 per share, for $1.3 million, at
- Exicure, Inc. Reports Second Quarter 2024 Financial ResultsExicure, Inc. (NASDAQ:XCUR, the ", Company", ))), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Second Quarter 2024 Financial Results Cash Position: Cash and cash equivalents were $0.5 million as of June 30, 2024, as compared to $0.8 million as of December 31, 2023. The Company believes that its cash and cash equivalents are insufficie
- Exicure, Inc. Reports First Quarter 2024 Financial ResultsExicure, Inc. (NASDAQ:XCUR, the "Company"))), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. First Quarter 2024 Financial Results Cash Position: Cash and cash equivalents were $0.4 million as of March 31, 2024, as compared to $0.8 million as of December 31, 2023. Subsequent to March 31, 2024, our cash and cash equivalents have decreased
- Exicure, Inc. Reports Full Year 2023 Financial ResultsExicure, Inc. (NASDAQ:XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. 2023 Financial Results Cash Position: Cash and cash equivalents were $0.8 million as of December 31, 2023, as compared to $8.6 million as of December 31, 2022. Subsequent to December 31, 2023, our cash and cash equivalents have decreased to approximately $0.2 mil
- Exicure, Inc. Reports Third Quarter 2023 Financial ResultsExicure, Inc. (NASDAQ:XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Third Quarter 2023 Financial Results Cash Position: Cash and cash equivalents were $0.9 million as of September 30, 2023, as compared to $8.6 million as of December 31, 2022. Subsequent to September 30, 2023, our cash and cash equivalents have decreased to appro
- Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateExicure, Inc. (NASDAQ:XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Corporate Update Recent highlights include: In May, the Company entered into two separate subscription agreements ("Subscription Agreements") with Cyworld Z Co., Ltd., ("Cyworld Z"). Pursuant to the Subscription Agreements, the Company purchased non-guarantee
- Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate UpdateExicure, Inc. (NASDAQ:XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Corporate Update Recent highlights include: On February 24, 2023, the Company received gross proceeds of $5.44 million from the September 2022 PIPE (net proceeds of $4.6 million after transaction expenses). As a result of the closing of the September 2022 PIP
- Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate UpdateExicure, Inc. (NASDAQ:XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the year ended December 31, 2022 and provided an update on its business strategy and corporate progress. Corporate Update As previously reported, in September 2022, we announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that we were exploring strategic alternatives to maximize stockholder value. With respect to our historical assets, this includes continuing to explore out-licensing opportunities for
- Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateExicure, Inc. (NASDAQ:XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today reported financial results for the quarter ended September 30, 2022 and provided an update on its business strategy and corporate progress. Corporate Update As previously reported, on September 26, 2022, the Company announced its commitment to a plan to wind down the Company's existing preclinical programs, including the development of its SCN9A program, to suspend all of its research and development activities, including suspension of all partnered programs, and to implement a reduction in force where the
- Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate ProgressCompany advancing SCN9A preclinical discovery program Exicure, Inc. (NASDAQ:XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological and hair loss disorders, today reported financial results for the quarter ended June 30, 2022 and provided an update on its business strategy and corporate progress. "Exicure continues to make progress with our preclinical SCN9A program for the treatment of pain with ongoing initial in vivo animal studies to support candidate selection in 2023," commented Matthias Schroff, Ph.D., Chief Executive Officer of Exicure. "We also continue to a
- Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate ProgressRecently announced a $5.0 million raise in a private placement transaction led by a subsidiary of CBI Co., Ltd. ("CBI"), a member of a leading investment group in South Korea focusing on assisting scientific-based companies in South Korea and the United States Exicure, Inc. (NASDAQ:XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today reported financial results for the quarter ended March 31, 2022 and provided an update on its business strategy and corporate progress. "Exicure is off to a promising start in 2022 as we have
- Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate ProgressExicure, Inc.® (NASDAQ:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter ended September 30, 2021 and provided an update on corporate progress. "I would first like to recognize the amazing work from the high-quality team members at Exicure as we continue to invest into driving value from our SNA platform technology, most notably being recognized in the third quarter through the consummation of another strategic partnership which brought in additional non-dilutive capital," said Exicure CEO Dr. David Giljohann. "It is important to note our SNA platform is grounded in 15 years o
- Exicure, Inc. Reports Second Quarter 2021 Financial Results and Corporate ProgressEntered Exclusive Collaboration with Ipsen Targeting Two Rare Neurodegenerative Disorders Presented Progress in Three Promising Neuroscience Programs including Friedreich's Ataxia, Neuropathic Pain and Batten Disease at R&D Day Announced Interim Results for Phase 1b/2 trial of Cavrotolimod (AST-008) and advancement of enrollment in MCC cohort Exicure, Inc.® (NASDAQ:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter ended June 30, 2021 and provided an update on corporate progress. "We continue to drive towards a number of key value inflection points across our platforms and p
- Exicure, Inc. Reports First Quarter 2021 Financial Results and Corporate Progress— Company Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients With Unmet Medical Needs — Exicure, Inc.® (NASDAQ:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter ended March 31, 2021 and provided an update on corporate progress. "Exicure is off to a strong start in 2021, as we continue to advance our clinical and pre-clinical programs and add depth to our Board of Directors and management team," commented Dr. David Giljohann, Exicure's Chief Executive Officer. "In the first quarter, cavrotolimod (AST-008) was granted two Fast Track designations